CardioFocus is launching a multi-center trial in Europe, testing its HeartLight balloon-based ablation system on 150 patients with drug-refractory, persistent atrial fibrillation. The study will test CardioFocus' device against standard radiofrequency ablation, completing enrollment by next May and planning a one-year follow-up. Meanwhile, CardioFocus is in the midst of a U.S. trial for FDA approval, aiming to wrap up enrollment this year. More